Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7283420 in Relapsed/Refractory AML
NCT04580121Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2020
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 1, open-label trial of RO7283420 in acute myeloid leukemia (AML), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 9 months, Percentage of Participants with Dose-Limiting Toxicities up to 28 days and 1 more. Started Nov 2020; status: completed.
02
Drugs
RO7283420
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04580121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580121.